Shamburg News · 8-K filed Nov 16, 2026, 8:30 AM EST

HCW Biologics Reports Third Quarter 2026 Financial Results and Clinical Development Highlights

HCWB · HCW Biologics Inc.

  • Earnings
  • Financial statements
  • Materiality: high

On November 16, 2026, HCW Biologics Inc. reported financial results for the quarter ended September 30, 2026. Third-quarter revenues were $55,463, compared with $15,606 a year earlier, and the net loss was $3,222,829, compared with $4,554,336. The company stated that substantial doubt exists about its ability to continue as a going concern without additional funding.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-052053.

Written from the filing by Shamburg Markets. Figures are as reported by the company.